Loyal as Veterinary Decision Engine

The big strategic shift here is from selling a longevity pill to owning the decision engine that tells vets which dogs to test, treat, and monitor over time. Loyal already runs a large multi year study with 1,000 plus senior dogs, routine lab work, and biomarker collection, which creates the raw material for age scoring panels or treatment matching tests. That would make Loyal look less like a single drug company and more like a veterinary care workflow company.

• Zoetis shows why diagnostics matter in animal health. It sells in clinic analyzers through VetScan and also operates reference labs, then uses those results to keep vets inside the Zoetis product stack for testing, interpretation, and treatment. It expanded that network through Abaxis, Ethos, Phoenix Lab, ZNLabs, and VPG.
  5 zoetis 6 zoetis 7 zoetis 8 zoetis
• For Loyal, a companion diagnostic could be very concrete. A vet draws blood during a senior wellness visit, sends it to a Loyal linked panel, gets back an aging or response profile, then decides whether LOY-002 or a large breed IGF-1 lowering drug fits that dog. The same panel could track whether the dog is responding after months on therapy.
  1 sacra 2 loyal 3 loyal 4 loyal
• This also changes customer economics. Instead of only earning monthly drug revenue, Loyal could add paid testing before treatment starts and during follow up visits. More importantly, the test would help vets explain why a healthy looking older dog should begin a preventive drug, which is a harder sale than treating an obvious disease.
  1 sacra 4 loyal 5 zoetis

The next phase is likely a bundled senior dog care model where screening, prescription choice, and ongoing monitoring are sold together. If Loyal can turn its trial biobank into a practical vet test, it can build a data advantage that is harder for larger animal health incumbents to copy than a single longevity drug alone.